Phase IV clinical application of Yikai tablet (pancreatic kininogenase enteric coated tablet), a key product of Qianhong pharmaceutical

Haitao, marketing director of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., said in the investigation that the company's main product, Yikai tablet (Pancreatic Kallidinogenase enteric coated tablet), had started phase IV clinical treatment recently Haitao said that the results so far are relatively ideal After completion, more clinicians can accept the product, and yikaipian will be widely promoted in China, "striving to upgrade the product from second-line diabetes medicine to first-line medicine, and achieving an average annual income growth of 30%." In 2013, yikaipian's tax free income was about 280 million yuan Yikai brand Pancreatic Kallidinogenase series products mainly include two dosage forms of Pancreatic Kallidinogenase enteric coated tablets and Pancreatic Kallidinogenase for injection, of which tablet is the key product of Qianhong pharmaceutical According to Haitao, yikaipian has covered more than 500 tertiary hospitals, more than 1000 secondary hospitals and more than 4000 central community hospitals in China "However, yikaipian's sales area is concentrated, with 60% of its sales concentrated in Beijing, Tianjin and Jiangsu Province, while other provinces have not yet fully opened their markets This year is the year of bidding, the company will increase the coverage of Yikai in blank provinces, such as Guangdong, Fujian, etc " Haitao said At the same time, under the trend of "Three Guarantees in one", the company will also increase the promotion of Yikai injection Haitao said that the combination of three guarantees and one Yikai injection is a great advantage As a medical insurance catalog product, the injection can be reimbursed by patients, so the promotion of the injection in county-level hospitals will be increased this year "Yikai sold more than 1 million injections last year, with a revenue of more than 30 million yuan We hope to achieve a sales scale of 100 million within three years."